uniQure sets November 4 results date for uniQure stock

Published on 10/29/2026 at 12:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter results are due before market open on November 4, 2026. uniQure stock costs EUR 22.25 at Lang & Schwarz on October 29, 2026.

Upcoming results and operating context

uniQure will report third-quarter 2026 results on November 4, 2026.
Second-quarter revenue reached USD 5.84 million versus USD 5.26 million a year earlier.
uniQure stock traded at EUR 22.25 at 12:31 p.m. CEST at Lang & Schwarz on October 29, 2026.
The earnings call is scheduled for 8:30 a.m. ET on November 4, 2026.

QURE, NL0010696654, Illustration mit AI erstellt.

uniQure (ISIN NL0010696654) will report third-quarter 2026 financial results before the market opens on November 4, 2026, according to GlobeNewswire. The company will host its earnings call at 8:30 a.m. ET. At 12:31 p.m. CEST on October 29, 2026, the stock traded at EUR 22.25 at Lang & Schwarz.

November 4 brings the next test

The scheduled report will give investors the next quantified update on uniQure's gene therapy pipeline and operating position. The company said the results will be released before the market opens, followed by management's conference call at 8:30 a.m. ET, according to GlobeNewswire.

Three dates define the setup

On July 29, 2026, uniQure reported second-quarter revenue of USD 5.84 million, up from USD 5.26 million a year earlier, while adjusted? The reported loss was USD 1.22 per share versus a consensus loss of USD 0.82, according to MarketBeat. On September 29, 2026, the company published a 48-month AMT-130 data update for Huntington's disease through its investor channel. On October 28, 2026, it announced the November 4 results date and the 8:30 a.m. ET call, according to GlobeNewswire.

What will November 4 clarify?

The report can put the USD 5.84 million second-quarter revenue figure into a new operating sequence and show whether the company is tracking toward the USD 6.18 million consensus revenue estimate for the third quarter. That estimate and the expected loss of USD 0.92 per share were published by MarketBeat.

Next reporting date is set

The next substantiated date is November 4, 2026, for the third-quarter results and the accompanying earnings call. For investors, the key comparison will be the reported revenue and loss against the USD 6.18 million and USD 0.92 per share consensus figures.

Stock trades in euros

uniQure's primary listing is Nasdaq, where the shares trade in USD. The finance profile identifies the company as a healthcare biotechnology group with a market capitalization of USD 1.7 billion as of October 28, 2026. The euro quotation stood at EUR 22.25 at Lang & Schwarz on October 29, 2026 at 12:31 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of uniQure stock.